Search
IMC-1C11
go.drugbank.com/drugs/DB06101ExperimentalIt is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction and inhibits VEGFR-induced endothelial cell proliferation.
Virginiamycin S1
go.drugbank.com/drugs/DB04805ExperimentalIt is used to treat infections with gram-positive organisms and as a growth promoter in cattle, swine, and poultry.
N-methylnicotinamide
go.drugbank.com/drugs/DB08840InvestigationalIt is a metabolite of niacinamide/nicotinamide and niacin/nicotinic acid (vitamin B3), and as such N-methylnicotinamide is used to diagnose niacin deficiency by measuring N-methylnicotinamide in the urine
Fluciclatide
go.drugbank.com/drugs/DB14842InvestigationalFluciclatide, an investigational radiotracer intended for PET imaging, was under investigation in clinical trials NCT00565721 and NCT01961583 to evaluate its ability to detect tumors and angiogenesis.
SynOV1.1
go.drugbank.com/drugs/DB17539InvestigationalIt is a recombinant oncolytic adenovirus, controlled by synthetic gene circuit, encoding the human immunostimulating factor cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF).
AEM-28-14
go.drugbank.com/drugs/DB17643ExperimentalAEM-28-14 is an analog of [AEM-28], an apolipoprotein E mimetic peptide, with a 400 percent greater cholesterol-lowering efficacy and a several-fold increase in drug tolerability. … [L45909] It is being investigated for lipid disorders such as homozygous familial hypercholesterolemia.[L45914]
Idraparinux
go.drugbank.com/drugs/DB06406InvestigationalIt was developed for the treatment and prevention of thromboembolic events. However, clinical trials have revealed that idraparinux had lead to bleeding.
Vabametkib
go.drugbank.com/drugs/DB21629InvestigationalVabametkib is under investigation in clinical trial NCT05541822 (To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET
PSN357
go.drugbank.com/drugs/DB05044ExperimentalPSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.
BHV-1300
go.drugbank.com/drugs/DB22673InvestigationalBHV-1300 is a IgG1,2,4 selective degrader being investigated for the treatment of Grave's disease.